Cara Therapeutics, Inc. (0HTC.L)
USD 0.25
(-1.15%)
USD 0.25
(-1.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 125.84 Million USD | -30.94% |
| 2022 | 182.23 Million USD | -26.24% |
| 2021 | 247.05 Million USD | -8.89% |
| 2020 | 271.15 Million USD | 16.4% |
| 2019 | 232.95 Million USD | 22.08% |
| 2018 | 190.82 Million USD | 96.72% |
| 2017 | 97 Million USD | 51.98% |
| 2016 | 63.82 Million USD | -42.44% |
| 2015 | 110.89 Million USD | 98.26% |
| 2014 | 55.93 Million USD | 209.32% |
| 2013 | 18.08 Million USD | 226.58% |
| 2012 | 5.53 Million USD | -48.18% |
| 2011 | 10.68 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 90.09 Million USD | -28.4% |
| 2024 Q2 | 72.49 Million USD | -19.54% |
| 2023 FY | 125.84 Million USD | -30.94% |
| 2023 Q2 | 134.38 Million USD | -12.32% |
| 2023 Q1 | 153.27 Million USD | -15.89% |
| 2023 Q3 | 115.33 Million USD | -14.18% |
| 2023 Q4 | 125.84 Million USD | 9.11% |
| 2022 Q1 | 223.86 Million USD | -9.39% |
| 2022 FY | 182.23 Million USD | -26.24% |
| 2022 Q4 | 182.23 Million USD | -14.65% |
| 2022 Q3 | 213.5 Million USD | -5.77% |
| 2022 Q2 | 226.57 Million USD | 1.21% |
| 2021 Q1 | 250.22 Million USD | -7.72% |
| 2021 Q3 | 225.09 Million USD | 1.64% |
| 2021 Q4 | 247.05 Million USD | 9.76% |
| 2021 FY | 247.05 Million USD | -8.89% |
| 2021 Q2 | 221.45 Million USD | -11.5% |
| 2020 Q1 | 196.17 Million USD | -15.79% |
| 2020 FY | 271.15 Million USD | 16.4% |
| 2020 Q3 | 147.13 Million USD | -12.74% |
| 2020 Q4 | 271.15 Million USD | 84.29% |
| 2020 Q2 | 168.61 Million USD | -14.05% |
| 2019 Q4 | 232.95 Million USD | -11.69% |
| 2019 FY | 232.95 Million USD | 22.08% |
| 2019 Q1 | 170.58 Million USD | -10.6% |
| 2019 Q2 | 149.64 Million USD | -12.28% |
| 2019 Q3 | 263.79 Million USD | 76.29% |
| 2018 Q2 | 139.89 Million USD | 73.49% |
| 2018 FY | 190.82 Million USD | 96.72% |
| 2018 Q4 | 190.82 Million USD | -10.29% |
| 2018 Q1 | 80.63 Million USD | -16.87% |
| 2018 Q3 | 212.7 Million USD | 52.05% |
| 2017 Q1 | 43.29 Million USD | -32.16% |
| 2017 Q3 | 108.04 Million USD | -8.41% |
| 2017 Q4 | 97 Million USD | -10.22% |
| 2017 FY | 97 Million USD | 51.98% |
| 2017 Q2 | 117.97 Million USD | 172.46% |
| 2016 Q2 | 92.04 Million USD | -9.77% |
| 2016 FY | 63.82 Million USD | -42.44% |
| 2016 Q1 | 102.01 Million USD | -8.01% |
| 2016 Q4 | 63.82 Million USD | -20.37% |
| 2016 Q3 | 80.15 Million USD | -12.92% |
| 2015 Q1 | 51.65 Million USD | -7.65% |
| 2015 FY | 110.89 Million USD | 98.26% |
| 2015 Q4 | 110.89 Million USD | -5.94% |
| 2015 Q3 | 117.89 Million USD | 153.86% |
| 2015 Q2 | 46.44 Million USD | -10.09% |
| 2014 Q3 | 62.37 Million USD | -8.54% |
| 2014 Q1 | 71.55 Million USD | 295.7% |
| 2014 FY | 55.93 Million USD | 209.32% |
| 2014 Q4 | 55.93 Million USD | -10.32% |
| 2014 Q2 | 68.19 Million USD | -4.7% |
| 2013 Q4 | 18.08 Million USD | -18.06% |
| 2013 Q2 | 25.27 Million USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 18.08 Million USD | 226.58% |
| 2013 Q3 | 22.06 Million USD | -12.69% |
| 2012 FY | 5.53 Million USD | -48.18% |
| 2012 Q4 | 5.53 Million USD | 0.0% |
| 2011 FY | 10.68 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 74.788% |
| Dynavax Technologies Corporation | 997.09 Million USD | 87.379% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 91.068% |
| Perrigo Company plc | 10.8 Billion USD | 98.836% |
| Illumina, Inc. | 10.11 Billion USD | 98.755% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.873% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 83.873% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.845% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.528% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 43.442% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.62% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -91.573% |
| Waters Corporation | 4.62 Billion USD | 97.28% |
| Biogen Inc. | 26.84 Billion USD | 99.531% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 23.879% |
| Evolus, Inc. | 188.99 Million USD | 33.415% |
| Adicet Bio, Inc. | 207.29 Million USD | 39.292% |
| bluebird bio, Inc. | 619.16 Million USD | 79.675% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 38.85% |
| FibroGen, Inc. | 423.52 Million USD | 70.287% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.831% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -345.113% |
| Homology Medicines, Inc. | 47.05 Million USD | -167.429% |
| Geron Corporation | 394.07 Million USD | 68.066% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 96.714% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 83.822% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 89.502% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 65.849% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 90.327% |
| Zoetis Inc. | 14.28 Billion USD | 99.119% |
| Abeona Therapeutics Inc. | 64 Million USD | -96.625% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 96.25% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 98.161% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.446% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -124.926% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 95.791% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 23.963% |
| Verastem, Inc. | 149.71 Million USD | 15.946% |
| Nektar Therapeutics | 398.03 Million USD | 68.384% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 78.607% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 36.251% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 96.145% |
| OPKO Health, Inc. | 2.01 Billion USD | 93.744% |
| Exelixis, Inc. | 2.94 Billion USD | 95.723% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 96.13% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 79.752% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 18.487% |
| uniQure N.V. | 831.68 Million USD | 84.869% |
| Imunon, Inc. | 21.91 Million USD | -474.156% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 88.006% |
| Insmed Incorporated | 1.32 Billion USD | 90.537% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 92.74% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 86.571% |
| TG Therapeutics, Inc. | 329.58 Million USD | 61.818% |
| Incyte Corporation | 6.78 Billion USD | 98.144% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 93.142% |